Pipeline

We are advancing a pipeline of first-in-class ‘CD8 Treg modulators’ designed to restore durable immune balance. Our lead program targets autoimmune mediated gastro-intestinal diseases where significant unmet needs for improved therapies continue to exist.

Pipeline

development pipeline graphic for desktop

development pipeline graphic for mobile

KIR Dependent CD8 Treg Modulator

In our lead program, MTX-101, we are developing a bispecific CD8 Treg modulator targeting inhibitory KIRs (Killer immunoglobulin-like receptors) and regulatory CD8 T cell specific markers. KIR dependent CD8 Treg modulators are designed to restore the intrinsic function of regulatory CD8 T cells in order to suppress the activation and proliferation of pathogenic CD4 T cells and eliminate them.

Celiac Disease

Celiac disease is a serious chronic autoimmune disease where the ingestion of gluten causes gastrointestinal inflammation resulting in damage to the lining of the small intestine and other complications. Approximately one in one hundred people worldwide is affected by this disease. There are no approved therapeutic treatments. Currently, the only measure that can be taken for celiac disease is lifelong adherence to a strict gluten-free diet. However, 50% of diagnosed patients continue to report symptoms even when on a gluten free diet.

IBD

Inflammatory bowel disease (IBD) is a group of chronic, and often life-threatening inflammatory disease of the gastrointestinal tract, which includes Crohn's disease, ulcerative colitis, and other conditions. It is characterized by episodes of intestinal inflammation. The irregular immune response in IBD that results in inflammation and tissue damage manifests a life-long and worsening impairment of structure and function of the gastrointestinal tract. Treatment option for patients afflicted by IBD are very limited, and a considerable number of patients fail to achieve clinical remission after treatment or lose response over time. In cases of extensive disease, bowel resection to remove portions of small or large intestine is the only remaining therapeutic intervention.